Acute Effects of Blackcurrant and Citrus Polyphenol Extracts on Postprandial Glycaemia (Glu-FX)

August 21, 2018 updated by: Lucozade Ribena Suntory

Acute Effects of Blackcurrant and Citrus Polyphenol Extracts on Postprandial Glycaemia: The Glu-FX Study

Large postprandial glucose responses are associated with increased risk of chronic diseases, including diabetes and cardiovascular disease. Our group have previously shown that fruit polyphenol extracts, when consumed immediately before a mixed carbohydrate meal, reduce postprandial glycaemia. The aim of this study is to investigate the effects of a blackcurrant polyphenol extract and citrus polyphenol extract (and their combination), on postprandial glycaemia, insulinaemia and gastrointestinal hormone concentrations following a mixed carbohydrate test meal. It is hypothesised that blackcurrant and citrus extracts alone will inhibit glycaemia compared to placebo, and a combination of the two will have a greater effect.

Study Overview

Detailed Description

Intake of carbohydrate-rich foods transiently increases blood glucose levels (known as postprandial glycaemia). Repeated high postprandial glucose responses are evidenced to dysregulate functional proteins, oxidative stress and pancreatic beta cell function; thus increasing the risk of diabetes and cardiovascular disease. Accordingly, meals that elicit a reduced, or more gradual, rise in blood glucose levels are desirable. Fruit polyphenols may help to limit the glucose excursion following a high carbohydrate meal. Previous research by our group has demonstrated that blackcurrant polyphenols significantly inhibited the average incremental area under the curve (T+0 to +30 min) of plasma glucose. Possible mechanisms include inhibition of intestinal enzymes and inhibition of intestinal glucose absorption by decreasing Sodium-glucose linked transporter 1 (SGLT-1) / Glucose transporter 2 (GLUT-2) glucose transporter activity. In vitro data suggests that citrus polyphenols may impact on carbohydrate metabolism by binding to starch molecules, however, effects on postprandial glycaemia are not yet known. Blackcurrants and citrus fruits have distinct polyphenol profiles and may therefore act on glucose homeostasis via different mechanisms. Blackcurrants are rich in anthocyanins and flavanols, whereas citrus fruits are rich in flavanones, hesperetin and naringenin. Theoretically, combining blackcurrant with citrus extracts may have synergistic effects.

The aim of this study is to investigate the effects of blackcurrant polyphenol extracts and citrus polyphenol extracts (and their combination), on postprandial glycaemia, insulinaemia and gastrointestinal hormone concentrations following a mixed carbohydrate test meal. It is hypothesised that blackcurrant and citrus extracts alone will inhibit glycaemia compared to placebo, a combination of the two will have a greater effect.

Study design: A randomised, controlled, double-blind, cross-over study will be conducted. Subjects will consume different drinks at 4 separate study visits. Drinks will contain either: blackcurrant extract (low dose), blackcurrant extract (high dose), citrus extract (low dose), blackcurrant and citrus extract (low dose + low dose), or placebo (no polyphenols). The study will utilise an incomplete block design. Subjects will consume the placebo drink and 3 out of 4 of the polyphenol-containing drinks during the study. At least a 7-day wash-out period will be required between study days. Baseline (fasted) blood samples will be taken in duplicate at T-10 min and T-5 min before consuming the test drink (T+0 min). Immediately following consumption of the drink, a mixed carbohydrate test meal will be consumed. Further blood samples will be collected at 10 min intervals for the first 30 min and then every 15 min until T+90 min and at T+120 min. Blood samples will be analysed for plasma glucose, insulin, glucose-dependent insulinotropic peptide (GIP), glucagon-like peptide 1 (GLP-1), peptide YY (PYY), C-peptide and nonesterified fatty acids (NEFA).

Study Type

Interventional

Enrollment (Actual)

32

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • England
      • London, England, United Kingdom, SE1 9NH
        • Metabolic Research Unit

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age: 18-70 years
  • Men and women
  • Healthy (free of diagnosed diseases listed in the exclusion criteria)
  • Body Mass Index 18-35 kg/m2
  • Able to understand the information sheet and willing to comply with study protocol
  • Able to give informed written consent

Exclusion Criteria:

  • Those diagnosed with Phenylketonuria (PKU)
  • Those with known or suspected food intolerances, allergies or hypersensitivity
  • Women who are known to be pregnant or who are intending to become pregnant over the course of the study
  • Women who are breast feeding
  • Participation in another clinical trial
  • Those who have donated blood within 3 months of the screening visit and participants for whom participation in this study would result in having donated more than 1500 millilitres of blood in the previous 12 months.
  • Full Blood Counts and Liver Function test results outside of the normal range.
  • Current smokers, or reported giving up smoking within the last 6 months
  • History of substance abuse or alcoholism
  • Reported history of Cardiovascular disease, diabetes (or fasting glucose ≥ 7.1 mmol/L), cancer, kidney, liver or bowel disease, gastrointestinal disorder or use of drug likely to alter gastrointestinal function
  • Unwilling to restrict consumption of specified high polyphenol foods for 48 h before the study
  • Weight change >3kg in preceding 2 months
  • Blood pressure ≥160/100 mmHg
  • Total cholesterol ≥ 7.5 mmol/L; fasting triacylglycerol concentrations ≥ 5.0 mmol/L
  • Medications that may interfere with the study: alpha-glucosidase inhibitors (acarbose: Glucobay), insulin sensitizing drugs (metformin: Glucophage, Glucophage SR, Eucreas, Janumet; thiazolidinediones: Actos, Competact), sulfonylureas (Daonil, Diamicron, Diamicron MR, Glibenese, Minodiab, Amaryl Tolbutamide), and lipid lowering drugs (statins, nicotinic acid, colestyramine anhydrous, ezetimibe, fibrates). Other medications should be reviewed by medical representative from KCL on a case by case basis.
  • Nutritional supplements that may interfere with the study: higher dose vitamins/minerals (>200% Recommend Nutrient Intake), B vitamins, Vitamin C, calcium, copper, chromium, iodine, iron, magnesium, manganese, phosphorus, potassium and zinc. Subjects already taking vitamin or minerals at a dose around 100% or less up to 200% of the RNI, or evening primrose/algal/fish oil supplements will be asked to maintain habitual intake patterns, ensuring that they take them every day and not sporadically. They will be advised not to stop taking supplements or start taking new supplements during the course of the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: CROSSOVER
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Treatment arm 1
Participants will receive the placebo, blackcurrant extract (low dose), blackcurrant extract (high dose), citrus extract (low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
Participants will consume a small beverage that contains blackcurrant extract (low dose) immediately before a high-carbohydrate meal.
Participants will consume a small beverage that contains no fruit extracts immediately before a high-carbohydrate meal.
Participants will consume a small beverage that contains citrus extract (low dose) immediately before a high-carbohydrate meal.
Participants will consume a small beverage that contains blackcurrant extract (high dose) immediately before a high-carbohydrate meal.
EXPERIMENTAL: Treatment arm 2
Participants will receive the placebo, citrus extract (low dose), blackcurrant extract (high dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
Participants will consume a small beverage that contains no fruit extracts immediately before a high-carbohydrate meal.
Participants will consume a small beverage that contains citrus extract (low dose) immediately before a high-carbohydrate meal.
Participants will consume a small beverage that contains blackcurrant extract (high dose) immediately before a high-carbohydrate meal.
Participants will consume a small beverage that contains blackcurrant and citrus extracts (low dose / low dose)immediately before a high-carbohydrate meal.
EXPERIMENTAL: Treatment arm 3
Participants will receive the placebo, blackcurrant extract (low dose), blackcurrant extract (high dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
Participants will consume a small beverage that contains blackcurrant extract (low dose) immediately before a high-carbohydrate meal.
Participants will consume a small beverage that contains no fruit extracts immediately before a high-carbohydrate meal.
Participants will consume a small beverage that contains blackcurrant extract (high dose) immediately before a high-carbohydrate meal.
Participants will consume a small beverage that contains blackcurrant and citrus extracts (low dose / low dose)immediately before a high-carbohydrate meal.
EXPERIMENTAL: Treatment arm 4
Participants will receive the placebo, blackcurrant extract (low dose), citrus extract (low dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
Participants will consume a small beverage that contains blackcurrant extract (low dose) immediately before a high-carbohydrate meal.
Participants will consume a small beverage that contains no fruit extracts immediately before a high-carbohydrate meal.
Participants will consume a small beverage that contains citrus extract (low dose) immediately before a high-carbohydrate meal.
Participants will consume a small beverage that contains blackcurrant and citrus extracts (low dose / low dose)immediately before a high-carbohydrate meal.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postprandial glycaemia (iAUC 0-30 min)
Time Frame: 30 min
The primary endpoint is iAUC 0-30 min for plasma glucose concentrations
30 min

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postprandial glycaemia: iAUC 0-120 min
Time Frame: 120 min
iAUC 0-120 min for plasma glucose concentrations
120 min
Postprandial glycaemia: iCmax
Time Frame: 120 min
iCmax for plasma glucose concentrations
120 min
Postprandial glycaemia: Tmax
Time Frame: 120 min
Tmax for plasma glucose concentrations
120 min
Postprandial glycaemia: absolute concentrations at specific time points
Time Frame: 120 min
Absolute concentrations at specific time points, for plasma glucose concentrations
120 min
Postprandial insulinemia: iAUC 0-30 min
Time Frame: 30 min
iAUC 0-30 min for serum insulin concentrations
30 min
Postprandial insulinemia: iAUC 0-120 min
Time Frame: 120 min
iAUC 0-120 min for serum insulin concentrations
120 min
Postprandial insulinemia: iCmax
Time Frame: 120 min
iCmax, for serum insulin concentrations
120 min
Postprandial insulinemia: Tmax
Time Frame: 120 min
Tmax for serum insulin concentrations
120 min
Postprandial insulinemia: absolute concentrations at specific time points
Time Frame: 120 min
Absolute concentrations at specific time points, for serum insulin concentrations
120 min
Postprandial C-peptide: iAUC 0-30 min
Time Frame: 30 min
iAUC 0-30 min for plasma C-peptide concentrations
30 min
Postprandial C-peptide: iAUC 0-120 min
Time Frame: 30 min
iAUC 0-120 min for plasma C-peptide concentrations
30 min
Postprandial C-peptide: iCmax
Time Frame: 120 min
iCmax for plasma C-peptide concentrations
120 min
Postprandial C-peptide: Tmax
Time Frame: 120 min
Tmax for plasma C-peptide concentrations
120 min
Postprandial C-peptide: Absolute concentrations at specific time points
Time Frame: 120 min
Absolute concentrations at specific time points, for plasma C-peptide concentrations
120 min
Postprandial non-esterified fatty acids (NEFA): iAUC 0-30 min
Time Frame: 30 min
iAUC 0-30 min for serum NEFA concentrations
30 min
Postprandial non-esterified fatty acids (NEFA): iAUC 0-120 min
Time Frame: 120 min
iAUC 0-120 min for serum NEFA concentrations
120 min
Postprandial non-esterified fatty acids (NEFA): iCmax
Time Frame: 120 min
iCmax for serum NEFA concentrations
120 min
Postprandial non-esterified fatty acids (NEFA): Tmax
Time Frame: 120 min
Tmax for serum NEFA concentrations
120 min
Postprandial non-esterified fatty acids (NEFA): Absolute concentrations at specific time points
Time Frame: 120 min
Absolute concentrations at specific time points, for serum NEFA concentrations
120 min
Postprandial blood glucose-dependent insulinotropic peptide (GIP): iAUC 0-30 min
Time Frame: 30 min
iAUC 0-30 min for plasma GIP concentrations
30 min
Postprandial blood glucose-dependent insulinotropic peptide (GIP): iAUC 0-120 min
Time Frame: 120 min
iAUC 0-120 min for plasma GIP concentrations
120 min
Postprandial blood glucose-dependent insulinotropic peptide (GIP): iCmax
Time Frame: 120 min
iCmax, for plasma GIP concentrations
120 min
Postprandial blood glucose-dependent insulinotropic peptide (GIP): Tmax
Time Frame: 120 min
Tmax for plasma GIP concentrations
120 min
Postprandial blood glucose-dependent insulinotropic peptide (GIP): Absolute concentrations at specific time points
Time Frame: 120 min
Absolute concentrations at specific time points, for plasma GIP concentrations
120 min
Postprandial blood Glucagon-like peptide 1 (GLP-1): iAUC 0-30 min
Time Frame: 30 min
iAUC 0-30 min for plasma GLP-1 concentrations
30 min
Postprandial blood Glucagon-like peptide 1 (GLP-1): iAUC 0-120 min
Time Frame: 120 min
iAUC 0-120 min, for plasma GLP-1 concentrations
120 min
Postprandial blood Glucagon-like peptide 1 (GLP-1): iCmax
Time Frame: 120 min
iCmax for plasma GLP-1 concentrations
120 min
Postprandial blood Glucagon-like peptide 1 (GLP-1): Tmax
Time Frame: 30 min
Tmax for plasma GLP-1 concentrations
30 min
Postprandial blood Glucagon-like peptide 1 (GLP-1): Absolute concentrations at specific time points
Time Frame: 120 min
Absolute concentrations at specific time points, for plasma GLP-1 concentrations
120 min
Postprandial blood peptide YY (PYY): iAUC 0-30 min
Time Frame: 30 min
iAUC 0-30 min for plasma PYY concentrations
30 min
Postprandial blood peptide YY (PYY): iAUC 0-120 min
Time Frame: 120 min
iAUC 0-120 minfor plasma PYY concentrations
120 min
Postprandial blood peptide YY (PYY): iCmax
Time Frame: 120 min
iCmax for plasma PYY concentrations
120 min
Postprandial blood peptide YY (PYY): Tmax
Time Frame: 120 min
Tmax for plasma PYY concentrations
120 min
Postprandial blood peptide YY (PYY): Absolute concentrations at specific time points
Time Frame: 120 min
Absolute concentrations at specific time points, for plasma PYY concentrations
120 min

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Food diary (estimated/unweighed)
Time Frame: 7-days, collected at screening
Habitual dietary intake analysis
7-days, collected at screening
VAS measures of the palatability of the study drink
Time Frame: 10 min following the test drink
Descriptive statistics
10 min following the test drink
VAS measures of mood, satiety and digestive comfort
Time Frame: 120 min
Descriptive statistics
120 min
Buccal mouth swab
Time Frame: One off sample, collected at screening
Future exploratory analysis of lactase activity via the derived allele at the European lactase persistence (LP) locus
One off sample, collected at screening

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

May 30, 2017

Primary Completion (ACTUAL)

February 1, 2018

Study Completion (ACTUAL)

June 1, 2018

Study Registration Dates

First Submitted

May 23, 2017

First Submitted That Met QC Criteria

June 8, 2017

First Posted (ACTUAL)

June 12, 2017

Study Record Updates

Last Update Posted (ACTUAL)

August 22, 2018

Last Update Submitted That Met QC Criteria

August 21, 2018

Last Verified

August 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • HVS-007

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Postprandial Period

Clinical Trials on Blackcurrant extract (low dose)

3
Subscribe